

WHO Prequalification Programme WHO PUBLIC ASSESSMENT REPORT (WHOPAR)

[HA743 trade name]*

Abacavir (as sulfate)/lamivudine 600 mg/300 mg tablets

[HA743 trade name], manufactured at Cipla Limited, India, was included in the WHO list of prequalified medicinal products for the treatment of HIV/AIDS on 10 March 2023.

[HA743 trade name] is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV) infection in adults, adolescents and children weighing at least 25 kg. Detailed information on the use of this product is described in the summary of product characteristics (SmPC), which can be found in this WHOPAR.

The active pharmaceutical ingredients of [HA743 trade name] are abacavir (as sulfate) and lamivudine.

The efficacy and safety of abacavir and lamivudine are well established based on extensive clinical experience in the treatment of HIV/AIDS.

For details on the uses of this product and for side effects and warnings, see Part 4 of this WHOPAR (summary of product characteristics).

On the basis of data submitted and public information on the use of abacavir and lamivudine in HIV/AIDS, the team of assessors advised that [HA743 trade name] is of acceptable quality, efficacy and safety to allow inclusion of [HA743 trade name] in the list of prequalified medicinal products.

Summary of prequalification status for [HA743 trade name]:

Initial acceptance	Date	Outcome
Status on PQ list	10 March 2023	listed
Quality	22 February 2023	MR
Bioequivalence	03 March 2023	MR
Safety, efficacy	NA	NA
GMP (re-)inspection		
APIs	12 April 2019	MR
API	22 November 2019	MR
FPP	23 October 2020	MR*
GCP/GLP (re-)inspection	21 September 2020	MR*
API: active pharmaceutical ingredient FPP: finished pharmaceutical product GCP: good clinical practice [quality standard] GLP: good laboratory practice [quality standard]	GMP: good manufacturing practice [quality standard] MR: meets requirements MR*: desk review (based on recent inspection reports) NA: not applicable, not available PQ: prequalification	

The table represents the status of relevant completed activities only.

* Trade names are not prequalified by WHO. This is the national medicines regulatory authority's responsibility.